1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsADRC Developmental Projects is sponsored by University of Pennsylvania Alzheimer's Disease Research Center (ADRC). The University of Pennsylvania (Penn) Alzheimer's Disease Research Center (ADRC) will fund developmental projects to support basic, translational, or clinical research within the theme of heterogeneity in the Alzheimer's Disease (AD) continuum.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
ADRC Developmental Projects | Alzheimer’s Disease Research Center | Perelman School of Medicine at the University of Pennsylvania ADRC Developmental Projects 2026-2027 ADRC Developmental Project Announcement The 2026-2027 ADRC Developmental Projects RFA is now available.
The University of Pennsylvania (Penn) Alzheimer’s Disease Research Center (ADRC) will fund up to two developmental projects in the 2026-2027 academic year, pending availability of funds , to support basic, translational or clinical research. Application deadline: February 2, 2026 Download the full RFA here.
ADRC Developmental Projects Each year, the University of Pennsylvania (Penn) Alzheimer’s Disease Research Center (ADRC) will fund up to two developmental projects, pending availability of funds, to support basic, translational or clinical research within the theme of heterogeneity in the Alzheimer’s Disease (AD) continuum.
Special emphasis will be given to projects that address the theme of AD heterogeneity, but consideration will also be given for projects that are more novel, offer an area of research underrepresented in the ADRC or at Penn, and are transdisciplinary, expanding the breadth of collaborations. For information about the former Penn ADCC pilot awards program click here.
Currently Funded Projects Clinical and pathological correlates of alpha-synuclein aggregation in Alzheimer’s disease PI: Thomas F. Tropea, DO, MPH, MTR Dementia due to Alzheimer’s disease (AD) is a devastating neurological disorder associated with the accumulation of tau and beta-amyloid in the brain. However, alpha-synuclein (aSyn) deposition that is typically associated with Parkinson’s disease commonly co-occurs in people with AD.
The co-occurrence of these pathologies in the brain has been associated with worse cognitive and functional outcomes. Until recently, measuring aSyn was only possible at autopsy. However, a novel approach called aSyn-seed amplification assay (aSyn-SAA) to measure aSyn in the cerebrospinal fluid is highly sensitive and specific for differentiating individuals with aSyn pathology from those without.
Here we propose to measure aSyn-SAA in the cerebrospinal fluid from people with neuropathology confirmed AD with and without aSyn pathology and separately in people who have been followed at the UPenn ADRC and have extensive clinical characterization.
The purpose is to validate in an independent cohort the association between aSyn-SAA and aSyn pathology, to further describe associations between aSyn-SAA and quantitative aSyn pathology in different brain regions, and to determine associations between aSyn-SAA and clinical progression.
These findings will support future research grant applications to understand how best to deploy the use of amyloid-specific therapies considering the potential impact of non-AD pathologies on AD course. Somatic instability of short tandem repeats in Alzheimer’s disease Alzheimer’s disease (AD) is a common yet devastating form of dementia that affects over 5 million Americans and will have increasing prevalence as our population ages.
Despite the profound impact of AD on our patients, their families, and society, we have very limited treatment options. Changes in our genetic sequence, or DNA, can alter our risk of developing AD. Understanding the genetics of AD will not only help predict risk of disease, but will uncover the factors that cause AD that could help us develop better treatments.
Our understanding of how these sequence changes affect AD risk has largely focused on simple single letter changes to our DNA sequence. However, there are more complex ways in which our DNA can differ, including changes in the one million repeated sequence elements called short tandem repeats (STRs), which have not been explored in AD.
I have already performed analyses in nearly 3,000 individuals with and without AD and identified thousands of STRs in our DNA that influence risk for AD. In this work, I study how these STRs may continue to mutate in the brains of patients with AD and whether this may lead to certain parts of the brain and/or cells in the brain to become more vulnerable to damage in AD.
Understanding what makes some cells and parts of the brain more vulnerable to damage in AD could help us develop treatments to slow or even stop degeneration in patients with AD. Overall, my work will uncover how these STRs contribute to damage in the brains of patients with AD. These insights that result from this work could lead to more effective treatment for this devastating condition.
Moreover, the approaches developed in this study can be broadly applied to other diseases such as heart disease and cancer. Single Extracellular Vesicle BEAMing for Early Diagnosis of Alzheimer’s Disease
According to the current listing, eligibility includes: Researchers affiliated with the University of Pennsylvania (Penn). Confirm the full requirements in the official notice before applying.
ADRC Developmental Projects is funded by University of Pennsylvania Alzheimer's Disease Research Center (ADRC). Verify program details on the funder's official page before applying.
This opportunity targets applicants in Pennsylvania. If your organization operates elsewhere, check the official notice for location requirements.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The full ASPECT NOFO (DE-FOA-0003647) posted September 4, 2026, eleven days later than the Notice of Intent predicted. The real document splits $58 million across two topic areas with anticipated award counts of 0-7 and 0-3, a cost share that jumps from 20 percent to 50 percent mid-project, a mandatory five-page concept paper due October 9, and a university eligibility restriction that decides team structure before anyone writes a word.
Read articleThe Humana Foundation's first 2026 slate funded 13 nonprofits and five university research teams around senior and veteran emotional health, with awards from $150,000 to $3 million concentrated in Texas, Florida, and Kentucky. A second health equity slate is planned for fall 2026. Here is what the portfolio structure reveals about how this funder decides, and how aging-services and behavioral health organizations should position.
Read articleThe Hydrocarbons and Geothermal Energy Office's University Training and Research program funds coal, oil and gas, and geothermal R&D at U.S. colleges and universities — but every proposal must include a non-academic partner and must build training modules that outlive the award. The LOI deadline is October 1, 2026, with full applications 15 days later. Here is what that compressed window means and why the workforce framing changes what a competitive proposal looks like.
Read article